Browse the evidence

Semaglutide can be used safely and efficiently in non-diabetic people with excess weight.

Semaglutide may be considered as a treatment option for weight management in non-diabetic patients.

Modest weight loss of 2-3% of body weight is recommended to improve therapeutic durability and prevent beta-cell deterioration.

Encouraging patients to achieve modest weight loss can enhance their diabetes management.

Participants lost an average of 12% of their initial body weight as a result of the intervention.

Practitioners can expect significant weight loss in participants following this lifestyle intervention.

The prevalence of metabolic syndrome decreased from 58% at baseline to 19% at follow-up among participants at the first intervention site.

This intervention can significantly reduce the prevalence of metabolic syndrome in similar populations.

Lifestyle interventions are feasible and deliver meaningful results in routine primary care practice.

Healthcare providers can implement lifestyle interventions in primary care settings to achieve positive health outcomes.

Physical activity reduces the risk of developing coronary heart disease, stroke, and type 2 diabetes.

Clinicians should encourage physical activity to reduce the risk of chronic diseases.

Endurance exercise positively influences muscle protein turnover rates in people with obesity.

Incorporating HIIT may help improve muscle health in individuals with obesity.

WG patients lost more weight than TC patients at 1 year (-13.21 pounds for WG vs +1.94 pounds for TC).

Group visit models may be more effective for weight loss compared to traditional care.

61% of WG patients lost a clinically relevant amount of weight (>5%) and 71% of those maintained at least half of their weight loss 3 years later.

Long-term weight loss maintenance is achievable through group wellness interventions.

After 12 weeks, participants in the psychological counseling group had lower body weight, relative fat mass, and higher free fat mass compared to the control group (p < 0.001 for all).

Incorporating psychological counseling may enhance physical outcomes in obese adolescents.

Training considerations inclusive of the extensors may benefit women who engage in resistance training as a means of mitigating risk for low back pain.

Incorporating extensor exercises can help practitioners reduce the risk of low back pain in their clients.

A produce prescription program significantly improved HbA1c among low-income patients on Medicaid with poor glycemic control at baseline.

Implementing produce prescription programs may help improve glycemic control in low-income diabetic patients.

HbA1c at 6 months was significantly reduced in the intervention group compared to control.

The intervention may be effective in lowering HbA1c levels in similar patient populations.

Low-load blood flow restriction (BFR) training is an effective strategy to increase muscular adaptations when performed during resistance training.

Practitioners can consider incorporating low-load BFR training into resistance training programs to enhance muscular adaptations.

The article aims to provide an evidence-based review of current research on BFR and its application for physique athletes.

Practitioners can refer to this review for insights on applying BFR to enhance muscle mass in athletes.

GLP-1 receptor agonists have demonstrated efficacy and safety in treating type 2 diabetes and obesity.

GLP-1 receptor agonists can be considered effective options for managing type 2 diabetes and obesity.

Ingestion of a 6.4% carbohydrate-electrolyte solution (CHO) significantly increased plasma glucose oxidation during running (65 ± 20 g.h−1) compared to water (W) (42 ± 16 g.h−1; p < 0.01).

For athletes, consuming carbohydrates before and during exercise can enhance glucose oxidation and potentially improve performance.

The contribution to total carbohydrate oxidation was significantly greater with CHO than W during running (33 ± 4% vs. 23 ± 3%; p < 0.01) and cycling (36 ± 5% vs. 22 ± 3%; p < 0.01).

Athletes should consider carbohydrate solutions to maximize carbohydrate oxidation during endurance activities.

New pharmacologic advances in glucagon-like peptide-1 agonists, such as semaglutide, have shown promising effectiveness for weight management.

Plastic surgeons should consider the role of GLP-1 agonists in managing obesity in surgical patients.

Semaglutide and tirzepatide are effective medication options for obesity management.

Practitioners can consider semaglutide and tirzepatide as viable options for treating obesity.

Patients in the semaglutide group experienced greater weight loss compared to the control group (−8.2% vs. −4.6%; P <0.001).

Semaglutide may be effective for weight management in patients post-ablation.

Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.

Tirzepatide may be a highly effective treatment option for managing glycaemic control and weight in patients with T2D and obesity.

Bariatric surgery effectively improves the management of obesity and inhibits the progression of multiple metabolic diseases.

Bariatric surgery should be considered as a viable option for managing obesity and related metabolic conditions.

With the inclusion of dietary supplements, percentages below the EAR for all nutrients (except protein) were lower than those for food alone.

Incorporating dietary supplements may help mitigate nutrient deficiencies in calorie-restricted diets.